Patients suffering from the rare neuromuscular disorder Lambert-Eaton myasthenic syndrome have recently received life changing news. On August 27, 2013 the FDA decided to grant Amifampridine Phosphate a Breakthrough Therapy Designation, also known as BTD. Marketed by BioMarin as the brand name Firdapse, Amifampridine Phosphate offers a crucial new hope for patients enduring this fatal[…]
Rare Breakthrough Therapy Designation for Amifampridine Phosphate
Cardiovascular Agent, Drug Research & Development API, FDA Approved 2010, FDA Breakthrough Therapy Status Tags: acetylcholine Sep 09, 2013
Treatments Available for Surge of Alzheimer’s Cases
Anti-Alzheimer's, Antidimentia, Drug Research & Development API Tags: 120014-06-441100-52-1acetylcholineAlzheimers diseaseDonepezilMemantine Jul 02, 2013
The approval of Aricept fifteen years ago was the last time there was anything new to treat the symptoms of Alzheimer’s disease. This lack of research and drug development is unnerving to patients and practitioners alike, with this lethal disease affecting 5.4 million Americans. On June 13, 2013 the BCC posted an alarming research report,[…]
Alzheimers Disease Is The Fastest Growing Health Threat To Americans
Anti-Alzheimer's, Antidimentia Tags: 120014-06-441100-52-1acetylcholineAlzheimers diseaseDonepezilMemantine Mar 12, 2013
Estimated Number of Cases of AD in the U.S. (millions). A report issued from the University of Washington in Seattle on March 5, 2013 revealed a startling statistic. The fastest growing health threat to Americans is not cancer or heart disease – it is Alzheimers disease! While this may not have been surprising information to[…]
Amifampridine is a New Treatment for Patients with Lambert-Eaton Myasthenic Syndrome
Cardiovascular Agent, FDA Approved 2010 Tags: acetylcholineEU Nov 26, 2012
Amifampridine, CAS# 54-96-6, is the first and only approved drug thus far for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome in adults. As a rare autoimmune disease, Lambert-Eaton Myasthenic Syndrome, also called LEMS, is typically caused by autoantibodies to voltage gated calcium channels, leading to a reduction in the amount of acetylcholine released from nerve[…]
Donepezil Showing Efficacy for Alzheimer's Disease and Lewy body Dementia
Bulk Active Ingredient, Drug Research & Development API Tags: 120014-06-4acetylcholineAlzheimers diseaseDonepezil Mar 07, 2012
Donepezil, CAS number 120014-06-4, is also marketed under the brand name Aricept, and is used in treatment of Alzheimer’s disease. Patients with dementia have low levels of the brain chemical acetylcholine, which is a crucial chemical for thinking and memory issues. Donepezil improves the patient’s nerve cell functioning by inhibiting the breakdown of acetylcholine. Aricept,[…]